<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571606</url>
  </required_header>
  <id_info>
    <org_study_id>19-3303</org_study_id>
    <nct_id>NCT04571606</nct_id>
  </id_info>
  <brief_title>Interscalene Catheter vs. Interscalene Liposomal Bupivacaine for Arthroscopic Rotator Cuff Repair</brief_title>
  <official_title>Interscalene Catheter vs. Interscalene Liposomal Bupivacaine for Arthroscopic Rotator Cuff Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arthroscopic rotator cuff repair often causes significant postoperative pain. An interscalene&#xD;
      nerve catheter is an effective and proven method to help reduce postoperative pain and&#xD;
      decrease opioid use around the time of shoulder surgery. Liposomal bupivacaine (Exparel) was&#xD;
      recently approved by the FDA for use around the interscalene brachial plexus, and it has been&#xD;
      shown to be an effective option, but its analgesic efficacy has limited data. Both techniques&#xD;
      are currently being used at the UNC's Ambulatory Surgery Center (ASC) for analgesia after&#xD;
      shoulder arthroscopy. The goal is to ensure that the fairly new Exparel option provides&#xD;
      non-inferior analgesia as compared to the prior standard practice of placing a nerve catheter&#xD;
      with plain bupivacaine. The investigators hope to ensure the quality of pain control around&#xD;
      the time of shoulder arthroscopy at this institution by prospectively and rigorously&#xD;
      collecting data during regular follow up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective comparison of patients undergoing rotator cuff repair that receive one&#xD;
      of two types of interscalene nerve block, both of which are currently being used at UNC.&#xD;
      Group 1 will be comprised of patients with a preoperative interscalene nerve catheter placed&#xD;
      with 20 mL 0.25% bupivacaine and a 0.2% ropivacaine infusion by an OnQ pain pump. Group 2&#xD;
      will be comprised of patients with a preoperative interscalene nerve block placed with 10 mL&#xD;
      0.5% bupivacaine and 10 mL 1.3% Liposomal Bupivacaine (Exparel). All patients in both groups&#xD;
      will have a similar intraoperative general anesthetic with multimodal analgesic pre-op oral&#xD;
      medications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2020</start_date>
  <completion_date type="Actual">July 2, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Recovery 15 Score (QOR15)</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>The QoR15 provides a valid, extensive, and efficient evaluation of postoperative quality of recovery. The QOR15 has 15 questions on a 0-10 point scale, so the QOR15 score can range from 0-150, the higher the score, the better the quality of recovery.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Opioid Dose in Morphine Equivalents</measure>
    <time_frame>postoperative days 1, 2 &amp; 3</time_frame>
    <description>total opioid administered over the first 3 postoperative days</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Patients with a Highest Pain Score &gt; 3</measure>
    <time_frame>postoperative days 1, 2 &amp; 3</time_frame>
    <description>Visual analog pain scores after operation [0-10, with 10 being the worst pain]</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-operative ultrasound guided interscalene nerve block with 10 mL 1.3% liposomal bupivacaine (Exparel) and 10 mL 0.5% bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peripheral Nerve Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-operative ultrasound guided interscalene nerve block with 20 mL of 0.25% bupivacaine and placement of peripheral nerve catheter with 10 mL/hr 0.2% bupivacaine infusion via OnQ pump.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single injection peripheral nerve block with liposomal bupivacaine (Exparel)</intervention_name>
    <description>10 mL/133 mg liposomal bupivacaine and 10 mL 0.5% bupivacaine</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single injection peripheral nerve block with 0.25% bupivacaine and subsequent peripheral nerve catheter with 0.2% bupivacaine infusion via onQ pain pump</intervention_name>
    <description>20 mL 0.25% bupivacaine block and subsequent 10 mL/hr 0.2% bupivacaine infusion for 48 hours</description>
    <arm_group_label>Peripheral Nerve Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients age &gt; 18 undergoing arthroscopic rotator cuff repair at the ambulatory&#xD;
             surgery center at the University of North Carolina&#xD;
&#xD;
        Exclusion Criteria: the below are simply contraindications to regional anesthesia in&#xD;
        general, this is a pragmatic study to evaluate the quality of care for these patients with&#xD;
        no additional exclusion criteria.&#xD;
&#xD;
          -  Contraindications to regional anesthesia&#xD;
&#xD;
          -  Significant peripheral neuropathy or neurological disorder affecting the upper&#xD;
             extremity&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Cognitive or psychiatric condition that might affect patient assessment and/or&#xD;
             inability to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Schoenherr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina Ambulatory Surgery Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.</ipd_description>
    <ipd_time_frame>9 to 36 months following publication</ipd_time_frame>
    <ipd_access_criteria>Approval from an IRB, IEC, or REB, as applicable, and an executed data use/sharing agreement with UNC</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

